Matches in SemOpenAlex for { <https://semopenalex.org/work/W1975423257> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W1975423257 endingPage "101" @default.
- W1975423257 startingPage "94" @default.
- W1975423257 abstract "Objectives: Conflicting reports exist as to the utility of PSP94 in the diagnosis and management of prostate cancer. We have identified serum-bound forms of PSP94 in prostate cancer patients. To further evaluate the usefulness of this finding, we measured bound and free serum PSP94 levels in patients with nonmetastatic prostate cancer before radiotherapy. Materials and Methods: Pretreatment levels of free PSP94 in 42 patients were measured in serum via a competitive enzyme-linked immunosorbent assay. Levels of bound PSP94 were measured by a semiquantitative assay after fractionation of total serum proteins by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blot analysis. Pretreatment levels of prostate specific antigen (PSA) were measured by a commercially available assay. Archival sera from 42 patients and a subgroup of 27 patients with “favorable” pretreatment PSA values (i.e., < 10 ng/ml) were statistically analyzed. Pretreatment levels of PSP94 (free and bound) and PSA, as well as tumor stage and grade, were correlated with treatment outcome (biochemical relapse-free survival) postradiotherapy. Results: Pretreatment PSA and the ratio of bound to free PSP94 were significant predictors of relapse postradiotherapy on univariate analysis. An elevated ratio of bound to free PSP94 was a stronger predictor (p = 0.0074) of relapse postradiotherapy compared with PSA level (p = 0.070) in a subgroup of prostate cancer patients with “favorable” pretreatment PSA levels. Conclusions: The results presented here indicate that serum PSP94-bound complexes must be considered in evaluating the clinical utility of PSP94 as a prostate cancer marker. A higher ratio of bound to free PSP94 may indicate worse outcome postradiotherapy. Differential testing of serum PSP94 has shown that it, in addition to PSA, may be of prognostic value for patients receiving radiotherapy for nonmetastatic prostate cancer." @default.
- W1975423257 created "2016-06-24" @default.
- W1975423257 creator A5019768466 @default.
- W1975423257 creator A5025134290 @default.
- W1975423257 creator A5046480395 @default.
- W1975423257 creator A5046888497 @default.
- W1975423257 creator A5062501400 @default.
- W1975423257 creator A5071042711 @default.
- W1975423257 creator A5079627883 @default.
- W1975423257 creator A5085140309 @default.
- W1975423257 date "2000-04-01" @default.
- W1975423257 modified "2023-10-16" @default.
- W1975423257 title "PSP94: Evaluation of Prognostic Utility in Patients Treated with Radiotherapy for Nonmetastatic Prostate Cancer" @default.
- W1975423257 doi "https://doi.org/10.1046/j.1525-1411.2000.22007.x" @default.
- W1975423257 hasPublicationYear "2000" @default.
- W1975423257 type Work @default.
- W1975423257 sameAs 1975423257 @default.
- W1975423257 citedByCount "6" @default.
- W1975423257 countsByYear W19754232572014 @default.
- W1975423257 countsByYear W19754232572021 @default.
- W1975423257 crossrefType "journal-article" @default.
- W1975423257 hasAuthorship W1975423257A5019768466 @default.
- W1975423257 hasAuthorship W1975423257A5025134290 @default.
- W1975423257 hasAuthorship W1975423257A5046480395 @default.
- W1975423257 hasAuthorship W1975423257A5046888497 @default.
- W1975423257 hasAuthorship W1975423257A5062501400 @default.
- W1975423257 hasAuthorship W1975423257A5071042711 @default.
- W1975423257 hasAuthorship W1975423257A5079627883 @default.
- W1975423257 hasAuthorship W1975423257A5085140309 @default.
- W1975423257 hasConcept C121608353 @default.
- W1975423257 hasConcept C126322002 @default.
- W1975423257 hasConcept C126894567 @default.
- W1975423257 hasConcept C143998085 @default.
- W1975423257 hasConcept C144301174 @default.
- W1975423257 hasConcept C2776235491 @default.
- W1975423257 hasConcept C2780192828 @default.
- W1975423257 hasConcept C2781406297 @default.
- W1975423257 hasConcept C38180746 @default.
- W1975423257 hasConcept C509974204 @default.
- W1975423257 hasConcept C71924100 @default.
- W1975423257 hasConcept C90924648 @default.
- W1975423257 hasConceptScore W1975423257C121608353 @default.
- W1975423257 hasConceptScore W1975423257C126322002 @default.
- W1975423257 hasConceptScore W1975423257C126894567 @default.
- W1975423257 hasConceptScore W1975423257C143998085 @default.
- W1975423257 hasConceptScore W1975423257C144301174 @default.
- W1975423257 hasConceptScore W1975423257C2776235491 @default.
- W1975423257 hasConceptScore W1975423257C2780192828 @default.
- W1975423257 hasConceptScore W1975423257C2781406297 @default.
- W1975423257 hasConceptScore W1975423257C38180746 @default.
- W1975423257 hasConceptScore W1975423257C509974204 @default.
- W1975423257 hasConceptScore W1975423257C71924100 @default.
- W1975423257 hasConceptScore W1975423257C90924648 @default.
- W1975423257 hasIssue "2" @default.
- W1975423257 hasLocation W19754232571 @default.
- W1975423257 hasOpenAccess W1975423257 @default.
- W1975423257 hasPrimaryLocation W19754232571 @default.
- W1975423257 hasRelatedWork W1980188241 @default.
- W1975423257 hasRelatedWork W1982816235 @default.
- W1975423257 hasRelatedWork W2038565121 @default.
- W1975423257 hasRelatedWork W2042911820 @default.
- W1975423257 hasRelatedWork W2055393917 @default.
- W1975423257 hasRelatedWork W2074491453 @default.
- W1975423257 hasRelatedWork W2084319043 @default.
- W1975423257 hasRelatedWork W2105000714 @default.
- W1975423257 hasRelatedWork W2152050874 @default.
- W1975423257 hasRelatedWork W2897445903 @default.
- W1975423257 hasVolume "2" @default.
- W1975423257 isParatext "false" @default.
- W1975423257 isRetracted "false" @default.
- W1975423257 magId "1975423257" @default.
- W1975423257 workType "article" @default.